Application Nr Approved Date Route Status External Links
ANDA091616 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Lithium Carbonate Extended-Release Tablets Are Indicated In The Treatment Of Manic Episodes Of Manic-Depressive Illness. Maintenance Therapy Prevents Or Diminishes The Intensity Of Subsequent Episodes In Those Manic-Depressive Patients With A History Of Mania. Typical Symptoms Of Mania Include Pressure Of Speech, Motor Hyperactivity, Reduced Need For Sleep, Flight Of Ideas, Grandiosity, Elation, Poor Judgment, Aggressiveness And Possibly Hostility. When Given To A Patient Experiencing A Manic Episode, Lithium Carbonate Extended-Release Tablets May Produce A Normalization Of Symptomatology Within 1 To 3 Weeks.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Lithium Carbonate LITHIUM CARBONATE ZINC895081

Comments